INT163134

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.65
First Reported 2004
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 78
Total Number 90
Disease Relevance 30.39
Pain Relevance 38.48

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (ACR) DNA binding (ACR) protein complex (ACR)
Anatomy Link Frequency
joints 8
superior 7
arm 5
white blood cell 1
ACR (Homo sapiens)
Pain Link Frequency Relevance Heat
methotrexate 2834 100.00 Very High Very High Very High
Pain 173 100.00 Very High Very High Very High
Infliximab 700 99.98 Very High Very High Very High
Etanercept 1128 99.70 Very High Very High Very High
abatacept 1947 99.48 Very High Very High Very High
Rheumatism 37 98.88 Very High Very High Very High
Inflammation 642 98.76 Very High Very High Very High
Adalimumab 1655 98.50 Very High Very High Very High
rheumatoid arthritis 3729 97.44 Very High Very High Very High
antagonist 287 97.44 Very High Very High Very High
Disease Link Frequency Relevance Heat
Disease 1688 100.00 Very High Very High Very High
Pain 169 100.00 Very High Very High Very High
Rheumatic Diseases 59 98.88 Very High Very High Very High
Arthritis 196 98.76 Very High Very High Very High
Rheumatoid Arthritis 3799 97.44 Very High Very High Very High
Seronegative Spondarthritis 622 96.48 Very High Very High Very High
Psoriasis 165 96.16 Very High Very High Very High
Increased Venous Pressure Under Development 144 95.76 Very High Very High Very High
Disease Progression 96 95.72 Very High Very High Very High
Ocular Toxicity (including Many Sub-types) 6 95.20 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Agreement (kappa) was poor to slight (</= 0.4) between most of the response measures with the exception of RADARA/ACR-20 which showed substantial agreement (0.67) and SDAI/EULAR-GM and CDAI/EULAR-GM, which showed moderate agreement (0.54 and 0.52, respectively).
Neg (exception) Gene_expression (exception) of ACR
1) Confidence 0.65 Published 2009 Journal Clin. Exp. Rheumatol. Section Body Doc Link 19772796 Disease Relevance 0 Pain Relevance 0
Anderlid et al refined the critical area to 100 kb in 22q13.33, which contains three genes, ProSAP2 (SHANK3), ACR (acrosin precursor) and RABL2B (RAB, member of RAS oncogene family-like 2B) [42].
Gene_expression (precursor) of acrosin
2) Confidence 0.65 Published 2010 Journal BMC Med Genet Section Body Doc Link PMC2892449 Disease Relevance 0.88 Pain Relevance 0.04
At 6 months, the primary endpoint showed that the AUC ACRn in the combination group was greater compared with the MTX group (18.3% years vs 12.2% years; p < 0.0001) with also a significant difference between the etanercept and MTX groups (14.7% years vs 12.2; p = 0.0034).
Gene_expression (group) of ACR associated with etanercept and methotrexate
3) Confidence 0.65 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721350 Disease Relevance 0.13 Pain Relevance 0.70
Seven genes reside in the duplicated area, which contains SHANK3, ACR, RABL2B, MAPK8IP2 (mitogen-activated protein kinase 8 interacting) and ARSA (arylsulfatase A, isoform b).
Gene_expression (contains) of ACR
4) Confidence 0.49 Published 2010 Journal BMC Med Genet Section Body Doc Link PMC2892449 Disease Relevance 0.63 Pain Relevance 0.03
Anderlid et al refined the critical area to 100 kb in 22q13.33, which contains three genes, ProSAP2 (SHANK3), ACR (acrosin precursor) and RABL2B (RAB, member of RAS oncogene family-like 2B) [42].
Gene_expression (precursor) of ACR
5) Confidence 0.49 Published 2010 Journal BMC Med Genet Section Body Doc Link PMC2892449 Disease Relevance 0.88 Pain Relevance 0.04
The percentages of patients in the group assigned to receive etanercept 25 mg who had ACR20, ACR50, and ACR70 responses were significantly greater than those in the methotrexate group at most evaluations within the first 6 months (P < 0.05) but were approximately the same thereafter [23].
Gene_expression (responses) of ACR50 associated with methotrexate and etanercept
6) Confidence 0.41 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC2833457 Disease Relevance 0.52 Pain Relevance 0.70
At 3.5 years, 69%, 50%, and 25% of patients had achieved ACR20, ACR50, and ACR70 responses, respectively [19].
Gene_expression (responses) of ACR50
7) Confidence 0.41 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC2833457 Disease Relevance 0.32 Pain Relevance 0.42
ACR20 is defined as a 20% improvement in tender and swollen joint counts and at least three of the following disease activity variables: patient's assessment of pain, patient's global assessment of disease activity, physician's global assessment of disease activity, patient's assessment of physical function, and ESR or CRP concentration [17].
Gene_expression (defined) of ACR20 in joint associated with pain and disease
8) Confidence 0.41 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC2833457 Disease Relevance 0.52 Pain Relevance 0.35
Patients who received the infliximab 10 mg/kg regimens also showed superior improvement in ACR20, ACR50, and ACR70 response, compared with controls, for up to 102 weeks [41].
Gene_expression (response) of ACR50 in superior associated with infliximab
9) Confidence 0.41 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC2833457 Disease Relevance 0.20 Pain Relevance 0.39
The percentages of patients in the group assigned to receive etanercept 25 mg who had ACR20, ACR50, and ACR70 responses were significantly greater than those in the methotrexate group at most evaluations within the first 6 months (P < 0.05) but were approximately the same thereafter [23].
Gene_expression (responses) of ACR20 associated with methotrexate and etanercept
10) Confidence 0.41 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC2833457 Disease Relevance 0.52 Pain Relevance 0.70
Patients who received the infliximab 10 mg/kg regimens also showed superior improvement in ACR20, ACR50, and ACR70 response, compared with controls, for up to 102 weeks [41].
Gene_expression (response) of ACR20 in superior associated with infliximab
11) Confidence 0.41 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC2833457 Disease Relevance 0.20 Pain Relevance 0.39
The percentages of patients in the group assigned to receive etanercept 25 mg who had ACR20, ACR50, and ACR70 responses were significantly greater than those in the methotrexate group at most evaluations within the first 6 months (P < 0.05) but were approximately the same thereafter [23].
Gene_expression (responses) of ACR70 associated with methotrexate and etanercept
12) Confidence 0.41 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC2833457 Disease Relevance 0.52 Pain Relevance 0.70
At 3.5 years, 69%, 50%, and 25% of patients had achieved ACR20, ACR50, and ACR70 responses, respectively [19].
Gene_expression (responses) of ACR20
13) Confidence 0.41 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC2833457 Disease Relevance 0.32 Pain Relevance 0.43
Additionally, those patients receiving 4 mg/kg or 8 mg/kg of tocilizumab in combination with MTX also achieved an ACR50 and ACR70 response that was significantly increased in comparison with MTX alone.
Gene_expression (response) of ACR50 associated with methotrexate
14) Confidence 0.38 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.07 Pain Relevance 0.36
Additionally, those patients receiving 4 mg/kg or 8 mg/kg of tocilizumab in combination with MTX also achieved an ACR50 and ACR70 response that was significantly increased in comparison with MTX alone.
Gene_expression (response) of ACR70 associated with methotrexate
15) Confidence 0.38 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.07 Pain Relevance 0.36
Patients who received the infliximab 10 mg/kg regimens also showed superior improvement in ACR20, ACR50, and ACR70 response, compared with controls, for up to 102 weeks [41].
Gene_expression (response) of ACR70 in superior associated with infliximab
16) Confidence 0.36 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC2833457 Disease Relevance 0.20 Pain Relevance 0.38
At 3.5 years, 69%, 50%, and 25% of patients had achieved ACR20, ACR50, and ACR70 responses, respectively [19].
Gene_expression (responses) of ACR70
17) Confidence 0.36 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC2833457 Disease Relevance 0.32 Pain Relevance 0.42
Additionally, more patients in the 8 mg/kg tocilizumab group achieved an ACR50 or ACR70 response compared with placebo.
Gene_expression (response) of ACR50
18) Confidence 0.33 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.27 Pain Relevance 0.25
The primary endpoint was achievement of an ACR20 response at week 12 using the last observation carried forward (LOCF) method.
Gene_expression (response) of ACR20
19) Confidence 0.33 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.44 Pain Relevance 0.09
The primary endpoint, an ACR20 response, was observed in a significantly higher proportion of patients receiving tocilizumab 4 mg/kg or 8 mg/kg (48% and 59%) versus methotrexate alone (26%).
Gene_expression (response) of ACR20 associated with methotrexate
20) Confidence 0.33 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.25 Pain Relevance 0.24

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox